Journal
AMERICAN JOURNAL OF HEMATOLOGY
Volume 86, Issue 10, Pages 879-882Publisher
WILEY-BLACKWELL
DOI: 10.1002/ajh.22136
Keywords
-
Categories
Funding
- NCI NIH HHS [P01 CA065493, P01-CA65493] Funding Source: Medline
Ask authors/readers for more resources
Allogeneic hematopoietic cell transplantation (allo-HCT) is often the only curative option for people with otherwise fatal hematologic malignancies. As the number of allo-HCT procedures continues to increase [1], it is increasingly clear that a major obstacle to success is delayed immune recovery, which puts patients at risk for a wide variety of opportunistic infections [2-8]. Additionally, rapid early lymphocyte recovery may serve as a surrogate predictor of better transplant outcomes. Robust recovery of absolute lymphocyte counts (ALC) early after transplantation is associated with improved survival following autologous, sibling, unrelated bone marrow, peripheral blood, and umbilical cord blood transplantation [9-15]. There is a clear need to develop strategies to accelerate and improve immune reconstitution (IR). Several novel approaches have been successfully tested in preclinical animal models and early human clinical trials. These include pretransplant androgen ablation, keratinocyte growth factor (KGF), and a p53 inhibitor or post-transplant administration of interleukin (IL)-7, IL-15, growth hormone, or insulin-like growth factor-1 [16-20].
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available